Literature DB >> 29161070

Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.

Elaine W Flagg1, Elizabeth A Torrone1.   

Abstract

OBJECTIVES: To detect decreases in anogenital warts (AGW) among sex and age groups likely to be affected by human papillomavirus vaccination.
METHODS: We estimated annual AGW prevalence during 2006 to 2014 using health care claims among US private health insurance enrollees aged 15 to 39 years. We derived AGW diagnoses using 1 of the following: (1) condylomata acuminata diagnosis, (2) viral wart diagnosis combined with a benign anogenital neoplasm diagnosis or destruction or excision of an anogenital lesion, or (3) AGW medication combined with a benign anogenital neoplasm diagnosis or destruction or excision of an anogenital lesion.
RESULTS: Prevalence decreased during 2008 to 2014 among females aged 15 to 19 years (annual percentage change [APC] = -14.1%; P < .001) and during 2009 to 2014 among women aged 20 to 24 years (APC = -12.9%; P < .001) and among women aged 25 to 29 years (APC = -6.0%; P = .001). We observed significant declines among men aged 20 to 24 years (APC = -6.5%; P = .005). Prevalence increased or was stable in all other sex and age groups.
CONCLUSIONS: We observed AGW decreases among females in the age groups most likely to be affected by human papillomavirus vaccination and decreases in men aged 20 to 24 years. Decreased prevalence in young men is likely attributable to herd protection from vaccination among females.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29161070      PMCID: PMC5719685          DOI: 10.2105/AJPH.2017.304119

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  35 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

Review 2.  Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.

Authors:  Geoffrey P Garnett
Journal:  J Infect Dis       Date:  2005-02-01       Impact factor: 5.226

3.  Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs.

Authors:  Philip E Castle; Fang-Hui Zhao
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

4.  Sexual mixing patterns in the spread of gonococcal and chlamydial infections.

Authors:  S O Aral; J P Hughes; B Stoner; W Whittington; H H Handsfield; R M Anderson; K K Holmes
Journal:  Am J Public Health       Date:  1999-06       Impact factor: 9.308

5.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

6.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

7.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.

Authors:  Laia Bruni; Mireia Diaz; Leslie Barrionuevo-Rosas; Rolando Herrero; Freddie Bray; F Xavier Bosch; Silvia de Sanjosé; Xavier Castellsagué
Journal:  Lancet Glob Health       Date:  2016-07       Impact factor: 26.763

8.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.

Authors:  Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-31       Impact factor: 17.586

9.  Cancer screening test use - United States, 2013.

Authors:  Susan A Sabatino; Mary C White; Trevor D Thompson; Carrie N Klabunde
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-08       Impact factor: 17.586

10.  Noninfluenza vaccination coverage among adults - United States, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-01       Impact factor: 17.586

View more
  16 in total

1.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

2.  Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.

Authors:  Anthony E Yakely; Lital Avni-Singer; Carlos R Oliveira; Linda M Niccolai
Journal:  Sex Transm Dis       Date:  2019-04       Impact factor: 2.830

3.  Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.

Authors:  L R Avni-Singer; A Yakely; S S Sheth; E D Shapiro; L M Niccolai; C R Oliveira
Journal:  Public Health       Date:  2019-11-04       Impact factor: 2.427

4.  Viral Venereal Diseases of the Skin.

Authors:  Theodora K Karagounis; Miriam K Pomeranz
Journal:  Am J Clin Dermatol       Date:  2021-05-18       Impact factor: 7.403

5.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

6.  Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015-2017.

Authors:  Rayleen M Lewis; Allison L Naleway; Nicola P Klein; Bradley Crane; Amber Hsiao; Laurie Aukes; Julius Timbol; Troy D Querec; Martin Steinau; Sheila Weinmann; Elizabeth R Unger; Lauri E Markowitz
Journal:  J Low Genit Tract Dis       Date:  2022-04-01       Impact factor: 3.842

7.  Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.

Authors:  Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke
Journal:  Cochrane Database Syst Rev       Date:  2019-11-22

8.  Condylomata Acuminata (Anogenital Warts) Contain Accumulations of HIV-1 Target Cells That May Provide Portals for HIV Transmission.

Authors:  Jeffrey Pudney; Zoon Wangu; Lori Panther; Dana Fugelso; Jai G Marathe; Manish Sagar; Joseph A Politch; Deborah J Anderson
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 7.759

9.  Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014.

Authors:  Meg Watson; Vicki Benard; Elaine W Flagg
Journal:  Prev Med Rep       Date:  2018-02-02

10.  Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States.

Authors:  Elissa Meites; Laura Stone; Raiza Amiling; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz
Journal:  Clin Infect Dis       Date:  2021-09-07       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.